Copytele Inc Stock OTC Bulletin Board
Equities
COPY
US2177211099
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Jun. 24 | Anixa Biosciences Says Sixth Patient Treated in Phase 1 Ovarian Cancer Study | MT |
Jun. 24 | Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 88.66M |
---|---|---|---|---|---|
Net income 2024 * | -13M | Net income 2025 * | -15M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.44
x | P/E ratio 2025 * |
-6.16
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.94% |
Latest transcript on Copytele Inc
Managers | Title | Age | Since |
---|---|---|---|
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Michael Catelani
DFI | Director of Finance/CFO | 57 | 16-10-31 |
Pamela Garzone
PRN | Corporate Officer/Principal | 70 | 21-09-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Titterton
BRD | Director/Board Member | 79 | 99-06-30 |
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Emily Gottschalk
BRD | Director/Board Member | 63 | 19-10-22 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+47.41% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ANIX Stock
- COPY Stock